Aurora Cannabis (US) ( (ACB) ) has released its Q2 earnings. Here is a breakdown of the information Aurora Cannabis (US) presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aurora Cannabis Inc., headquartered in Edmonton, Alberta, is a prominent player in the global medical cannabis sector, serving markets in Canada, Europe, Australia, and New Zealand. The company is known for its commitment to high-quality cannabis products and innovative approaches in both medical and consumer markets.
In its fiscal 2026 second quarter report, Aurora Cannabis announced a significant year-over-year increase in global medical cannabis net revenue, reaching a record $70.5 million. The company also reported a 52% growth in adjusted EBITDA, highlighting its strategic focus on the medical cannabis sector as a primary growth area.
Key financial metrics from the report include an 11% increase in total net revenue to $90.4 million, driven by a 15% growth in the global medical cannabis business and a 34% rise in plant propagation revenue. However, consumer cannabis revenue saw a decline due to strategic prioritization of higher-margin medical cannabis. The company maintained a strong balance sheet with $141.9 million in cash and a debt-free cannabis business, despite a net loss of $53.2 million from continuing operations.
Looking ahead, Aurora Cannabis management remains optimistic about continued growth, supported by a robust cash position and strategic focus on high-margin medical cannabis markets. The company anticipates further revenue growth in the coming quarters, driven by its leadership in key international markets and ongoing operational efficiencies.